Fusion Antibodies are CIR approved

CIR Approved

Fusion Antibodies has been granted approval to participate in the Crédit Impôt Recherche (CIR) scheme, meaning our French clients can enjoy a significant tax break by partnering with us for pre-clinical antibody research.

Based on Article 244 quarter B of the French Fiscal code, French Partners can benefit from a tax credit of 30% of the cost for R&D services. The tax credit covers costs including salaries, social security contributions, amortization and depreciation allowances, operating costs, subcontracting, patents and monitoring. For further details on the CIR tax credit, click here.

Julie Gormley, Sales Director for Fusion Antibodies, commented: “We are delighted to secure CIR approval to be able to offer our French customers access to this substantial tax break. Successful antibody development depends on getting things right from the outset and at Fusion Antibodies we have vast experience in the pre-clinical stages which will ultimately contribute towards a more successful outcome at clinical trial”.

To learn more about partnering with Fusion Antibodies for pre-clinical research, click below.